AORT

Artivion Inc

Feb 26 • 04:00PM ET

38.08

+2.30 6.43 %

Healthcare • Medical Devices • USA • NYSE

Peers: MDT ABT EW SYK BSX ISRG ZBH TFX NVCR IART

| Held by: IJR VTI IWM VXF SPSM IJT IWO VTWO SLYG SCHA

Index	RUT	P/E	190.69	EPS (ttm)	0.20	Insider Own	4.61%	Shs Outstand	47.84M	Perf Week	0.21%
Market Cap	1.82B	Forward P/E	50.29	EPS next Y	0.76	Insider Trans	-14.02%	Shs Float	45.68M	Perf Month	-8.20%
Enterprise Value	2.02B	PEG	0.83	EPS next Q	0.03	Inst Own	90.28%	Short Float	3.59%	Perf Quarter	-16.87%
Income	9.76M	P/S	4.13	EPS this Y	70.07%	Inst Trans	0.05%	Short Ratio	4.29	Perf Half Y	-13.51%
Sales	441.33M	P/B	4.06	EPS next Y	112.00%	ROA	1.17%	Short Interest	1.64M	Perf YTD	-16.51%
Book/sh	9.37	P/C	28.09	EPS next 5Y	60.30%	ROE	2.69%	52W High	48.25 -21.08%	Perf Year	49.80%
Cash/sh	1.36	P/FCF	2170.74	EPS past 3/5Y	- -	ROIC	1.39%	52W Low	21.97 73.33%	Perf 3Y	194.28%
Dividend Est.	-	EV/EBITDA	32.27	Sales past 3/5Y	12.04% 11.75%	Gross Margin	61.28%	Volatility	5.00% 4.31%	Perf 5Y	50.81%
Dividend TTM	-	EV/Sales	4.57	EPS Y/Y TTM	165.41%	Oper. Margin	9.07%	ATR (14)	1.71	Perf 10Y	261.29%
Dividend Ex-Date	Dec 09, 2015	Quick Ratio	2.08	Sales Y/Y TTM	13.59%	Profit Margin	2.21%	RSI (14)	43.72	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.99	EPS Q/Q	112.45%	SMA20	-2.03%	Beta	1.60	Target Price	51.43
Payout	0.00%	Debt/Eq	0.58	Sales Q/Q	19.20%	SMA50	-10.14%	Rel Volume	1.44	Prev Close	35.78
Employees	1800	LT Debt/Eq	0.56	Earnings	Feb 12 AMC	SMA200	-2.66%	Avg Volume	381.83K	Price	38.08
IPO	Feb 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.71% -0.41%	Trades		Volume	548,655	Change	6.43%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Downgrade	Ladenburg Thalmann	Buy → Neutral	$38.80
Jun-17-25	Initiated	Canaccord Genuity	Buy	$35
Oct-23-24	Initiated	JMP Securities	Mkt Outperform	$33
Sep-27-22	Reiterated	Lake Street	Buy	$32 → $28
Aug-08-22	Initiated	Lake Street	Buy	$32
Mar-03-22	Initiated	Stifel	Buy	$30

Feb-19-26 12:32AM	5 Must-Read Analyst Questions From Artivion's Q4 Earnings Call (StockStory)
Feb-13-26 11:30AM	Artivion (AORT) Stock Trades Down, Here Is Why (StockStory) -9.96%
08:30AM	Artivion, Inc. Q4 2025 Earnings Call Summary (Moby)
12:32AM	AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline (StockStory)
12:05AM	Artivion Inc (AORT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges (GuruFocus.com)
10:10PM	Loading…
Feb-12-26 10:10PM	Artivion Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Artivion (AORT) Q4 Earnings Surpass Estimates (Zacks)
04:58PM	Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations (StockStory)
04:36PM	Artivion: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Artivion Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-10-26 10:08PM	What To Expect From Artivion's (AORT) Q4 Earnings (StockStory)
Feb-02-26 08:00AM	Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting (PR Newswire)
Jan-29-26 04:05PM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results (PR Newswire)
Jan-05-26 12:51PM	Here's Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
Jan-01-26 11:02PM	3 Reasons to Sell AORT and 1 Stock to Buy Instead (StockStory)
10:42AM	Loading…
Dec-30-25 10:42AM	RBOT Enters Strategic Software Partnership to Streamline Development (Zacks)
Dec-29-25 09:40AM	Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-28-25 11:35PM	1 Safe-and-Steady Stock on Our Watchlist and 2 We Avoid (StockStory)
Dec-26-25 12:20PM	EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy (Zacks)
Dec-17-25 03:40PM	Artivion (AORT) Stock Is Up, What You Need To Know (StockStory)
12:01PM	HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases (Zacks)
Dec-12-25 09:40AM	Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-11-25 10:06AM	ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries (Zacks)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
Nov-26-25 09:40AM	Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-25-25 10:38PM	Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest (StockStory)
Nov-13-25 12:36AM	5 Must-Read Analyst Questions From Artivion's Q3 Earnings Call (StockStory)
Nov-07-25 09:26AM	AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook (StockStory) -5.54%
12:01AM	Artivion Inc (AORT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-25 06:15PM	Artivion (AORT) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:15PM	Loading…
05:15PM	Artivion: Q3 Earnings Snapshot (Associated Press Finance)
04:33PM	Artivion's (NYSE:AORT) Q3 Sales Top Estimates (StockStory)
04:05PM	Artivion Reports Third Quarter 2025 Financial Results (PR Newswire)
08:00AM	Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial (PR Newswire)
Nov-05-25 08:50AM	Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:19PM	Artivion (AORT) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-29-25 04:10PM	Artivion to Participate in the Stifel 2025 Healthcare Conference (PR Newswire)
08:09AM	Strong Results and Improved Guidance Lifted Artivion (AORT) (Insider Monkey)
Oct-23-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results (PR Newswire)
Oct-15-25 11:33PM	Firing on All Cylinders: Artivion (NYSE:AORT) Q2 Earnings Lead the Way (StockStory)
12:02AM	3 Reasons to Sell AORT and 1 Stock to Buy Instead (StockStory)
Oct-13-25 08:00AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting (PR Newswire)
Sep-25-25 08:48AM	Are Options Traders Betting on a Big Move in Artivion Stock? (Zacks)
Sep-05-25 04:10PM	Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
Aug-14-25 01:35AM	5 Must-Read Analyst Questions From Artivion's Q2 Earnings Call (StockStory)
Aug-12-25 10:01AM	1 Safe-and-Steady Stock to Target This Week and 2 We Find Risky (StockStory)
Aug-11-25 09:40AM	AORT Q2 Deep Dive: Product Momentum and Pipeline Advances Drive Upgraded Guidance (StockStory)
Aug-09-25 10:05AM	Artivion price target raised to $45 from $32 at Needham (TipRanks)
Aug-08-25 12:21PM	Why Is Artivion (AORT) Stock Rocketing Higher Today (StockStory) +25.23%
04:51AM	Artivion (NYSE:AORT) Reports Strong Q2, Stock Jumps 13.1% (StockStory)
Aug-07-25 06:05PM	Artivion (AORT) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	Artivion: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Artivion Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-06-25 02:51PM	Artivion (AORT) Stock Is Up, What You Need To Know (StockStory)
Aug-05-25 11:03PM	What To Expect From Artivion's (AORT) Q2 Earnings (StockStory)
Jul-31-25 12:02AM	3 Reasons AORT is Risky and 1 Stock to Buy Instead (StockStory)
Jul-30-25 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-29-25 05:20PM	Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-24-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results (PR Newswire)
Jul-23-25 12:33AM	3 Healthcare Stocks with Warning Signs (StockStory)
Jul-21-25 12:30PM	[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Jun-26-25 05:50PM	The 5 Most Interesting Analyst Questions From Artivion's Q1 Earnings Call (StockStory)
Jun-03-25 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
May-28-25 11:33PM	Q1 Earnings Highs And Lows: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
05:51PM	Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock (PR Newswire)
May-19-25 07:40AM	AORT Q1 Earnings Call: Early Product Launches and Supply Recovery Drive Outperformance (StockStory)
May-14-25 04:01PM	Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock (PR Newswire)
May-05-25 05:45PM	Artivion (AORT) Lags Q1 Earnings Estimates (Zacks) +15.36%
04:05PM	Artivion Reports First Quarter 2025 Financial Results (PR Newswire)
07:00AM	Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting (PR Newswire)
Apr-29-25 09:05AM	3 Stocks Under $50 That Concern Us (StockStory)
Apr-21-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results (PR Newswire)
Apr-15-25 05:11AM	Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
Apr-10-25 09:10AM	Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength? (Zacks)
Mar-28-25 05:04AM	Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-24-25 12:20PM	Do Options Traders Know Something About Artivion (AORT) Stock We Don't? (Zacks)
Mar-04-25 04:05PM	Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference (PR Newswire)
Feb-27-25 09:35AM	Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround (Zacks)
Feb-26-25 10:01AM	Artivion price target lowered to $32 from $34 at Needham (TipRanks)
Feb-24-25 04:05PM	Artivion Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -8.22%
Feb-10-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Jan-27-25 08:00AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting (PR Newswire)
Jan-20-25 03:23PM	Is Artivion, Inc. (AORT) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 08:00AM	Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis (PR Newswire)
Nov-07-24 04:05PM	Artivion Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-05-24 04:15PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire) +5.56%
Oct-24-24 04:15PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results (PR Newswire)
Oct-10-24 04:10PM	Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting (PR Newswire)
Aug-08-24 04:05PM	Artivion Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-05-24 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-25-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results (PR Newswire)
Jul-03-24 08:00AM	3 Earnings All-Stars With More Room to Run (InvestorPlace)
Jul-01-24 04:05PM	Artivion Amends Agreements with Endospan (PR Newswire)
Jun-18-24 09:28AM	Do You Think Artivion (AORT) Stock Could Soar? (Insider Monkey)
May-08-24 09:15AM	Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-07-24 09:49AM	Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call Transcript (Insider Monkey) +12.81%
May-06-24 05:20PM	Artivion (AORT) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:05PM	Artivion Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 08:05AM	Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting (PR Newswire)
Apr-22-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results (PR Newswire)

Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horton Amy	VP, Chief Accounting Officer	Feb 23 '26	Sale	37.59	1,731	65,065	128,327	Feb 25 05:43 PM
Horton Amy	VP, Chief Accounting Officer	Feb 24 '26	Sale	35.69	830	29,625	127,497	Feb 25 05:43 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 23 '26	Sale	37.59	2,423	91,076	43,180	Feb 25 05:36 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 24 '26	Sale	35.69	1,259	44,937	41,921	Feb 25 05:36 PM
Holloway Jean F	SVP, General Counsel	Feb 23 '26	Sale	37.59	3,079	115,733	153,871	Feb 25 05:35 PM
Holloway Jean F	SVP, General Counsel	Feb 24 '26	Sale	35.69	1,668	59,536	152,203	Feb 25 05:35 PM
Mackin James P	President & CEO	Feb 23 '26	Sale	37.59	20,962	787,920	780,031	Feb 25 05:34 PM
Mackin James P	President & CEO	Feb 24 '26	Sale	35.69	13,936	497,418	766,095	Feb 25 05:34 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Feb 23 '26	Sale	37.59	4,981	187,226	148,450	Feb 25 05:31 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Feb 24 '26	Sale	35.69	4,485	160,083	143,965	Feb 25 05:31 PM
Davis John E	Chief Commercial Officer	Feb 23 '26	Sale	37.59	3,773	141,820	190,943	Feb 25 05:30 PM
Davis John E	Chief Commercial Officer	Feb 24 '26	Sale	35.69	2,075	74,063	188,868	Feb 25 05:30 PM
Davis John E	Officer	Feb 24 '26	Proposed Sale	35.69	2,075	74,063		Feb 24 05:05 PM
Berry Lance A	Officer	Feb 24 '26	Proposed Sale	35.69	4,485	160,083		Feb 24 04:42 PM
Holloway Jean F	Officer	Feb 24 '26	Proposed Sale	35.69	1,668	59,536		Feb 24 04:41 PM
Mackin James P	Officer	Feb 24 '26	Proposed Sale	35.69	13,936	497,416		Feb 24 04:33 PM
Stanton Marshall S.	Officer	Feb 24 '26	Proposed Sale	35.69	1,259	44,937		Feb 24 04:20 PM
Horton Amy	Officer	Feb 24 '26	Proposed Sale	35.69	830	29,625		Feb 24 04:14 PM
Horton Amy	Officer	Feb 23 '26	Proposed Sale	37.59	1,731	65,064		Feb 23 04:52 PM
Mackin James P	Officer	Feb 23 '26	Proposed Sale	37.59	20,962	787,909		Feb 23 04:48 PM
Holloway Jean F	Officer	Feb 23 '26	Proposed Sale	37.59	3,079	115,732		Feb 23 04:40 PM
Davis John E	Officer	Feb 23 '26	Proposed Sale	37.59	3,773	141,818		Feb 23 04:39 PM
Berry Lance A	Officer	Feb 23 '26	Proposed Sale	37.59	4,981	187,223		Feb 23 04:31 PM
Stanton Marshall S.	Officer	Feb 23 '26	Proposed Sale	37.59	2,423	91,075		Feb 23 04:22 PM
Davis John E	Chief Commercial Officer	Dec 15 '25	Sale	45.11	5,000	225,550	193,842	Dec 17 03:47 PM
Davis John E	Officer	Dec 15 '25	Proposed Sale	45.11	5,000	225,554		Dec 17 02:50 PM
Horton Amy	VP, Chief Accounting Officer	Dec 08 '25	Sale	44.42	4,572	203,084	130,058	Dec 09 04:59 PM
Horton Amy	Officer	Dec 08 '25	Proposed Sale	44.42	4,572	203,081		Dec 08 03:16 PM
Mackin James P	President & CEO	Dec 03 '25	Option Exercise	29.62	30,921	915,880	831,914	Dec 04 08:54 PM
Mackin James P	President & CEO	Dec 03 '25	Sale	45.46	30,921	1,405,700	800,993	Dec 04 08:54 PM
Holloway Jean F	SVP, General Counsel	Dec 03 '25	Sale	45.30	7,315	331,370	156,093	Dec 04 08:52 PM
Mackin James P	President & CEO	Dec 02 '25	Option Exercise	29.62	30,921	915,880	831,914	Dec 03 07:27 PM
Mackin James P	President & CEO	Dec 02 '25	Sale	45.56	30,921	1,408,730	800,993	Dec 03 07:27 PM
Mackin James P	Officer	Dec 03 '25	Proposed Sale	45.46	30,921	1,405,695		Dec 03 05:10 PM
JEAN F HOLLOWAY	Officer	Dec 03 '25	Proposed Sale	45.30	7,315	331,391		Dec 03 04:06 PM
Mackin James P	Officer	Dec 02 '25	Proposed Sale	46.27	30,921	1,430,715		Dec 02 10:07 AM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 21 '25	Option Exercise	14.21	47,376	672,988	71,828	Nov 24 05:23 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 21 '25	Sale	45.04	47,376	2,133,920	44,753	Nov 24 05:23 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 20 '25	Option Exercise	15.48	3,388	52,434	46,786	Nov 24 09:35 AM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 20 '25	Sale	44.18	15,276	674,825	44,753	Nov 24 09:35 AM
Stanton Marshall S.	Officer	Nov 21 '25	Proposed Sale	45.04	47,376	2,133,936		Nov 21 04:34 PM
Stanton Marshall S.	Officer	Nov 20 '25	Proposed Sale	44.18	15,276	674,833		Nov 20 04:15 PM
Hoff Elizabeth A	Director	Nov 18 '25	Sale	45.10	4,200	189,412	27,189	Nov 19 01:49 PM
ELIZABETH A HOFF	Director	Nov 18 '25	Proposed Sale	45.10	4,200	189,413		Nov 18 04:05 PM
Holloway Jean F	SVP, General Counsel	Nov 17 '25	Option Exercise	29.62	6,394	189,390	169,802	Nov 18 01:11 PM
Holloway Jean F	SVP, General Counsel	Nov 14 '25	Option Exercise	29.62	6,393	189,361	169,801	Nov 18 01:11 PM
Holloway Jean F	SVP, General Counsel	Nov 17 '25	Sale	45.17	6,394	288,817	163,408	Nov 18 01:11 PM
Holloway Jean F	SVP, General Counsel	Nov 14 '25	Sale	45.00	6,393	287,685	163,408	Nov 18 01:11 PM
Davis John E	Chief Commercial Officer	Nov 17 '25	Option Exercise	29.62	6,394	189,390	205,236	Nov 18 01:03 PM
Davis John E	Chief Commercial Officer	Nov 14 '25	Option Exercise	29.62	6,393	189,361	205,235	Nov 18 01:03 PM
Davis John E	Chief Commercial Officer	Nov 17 '25	Sale	45.17	6,394	288,817	198,842	Nov 18 01:03 PM
Davis John E	Chief Commercial Officer	Nov 14 '25	Sale	44.67	6,393	285,575	198,842	Nov 18 01:03 PM
Horton Amy	VP, Chief Accounting Officer	Nov 17 '25	Sale	45.73	6,000	274,380	135,380	Nov 18 12:57 PM
Davis John E	Officer	Nov 17 '25	Proposed Sale	45.17	6,394	288,817		Nov 17 12:36 PM
Horton Amy	Officer	Nov 17 '25	Proposed Sale	45.73	6,000	274,382		Nov 17 12:23 PM
Holloway Jean F	Officer	Nov 17 '25	Proposed Sale	45.17	6,394	288,817		Nov 17 12:04 PM
Holloway Jean F	Officer	Nov 14 '25	Proposed Sale	45.00	6,393	287,685		Nov 14 02:51 PM
Horton Amy	VP, Chief Accounting Officer	Nov 13 '25	Sale	45.86	3,482	159,678	141,380	Nov 14 02:28 PM
Davis John E	Chief Commercial Officer	Nov 13 '25	Sale	45.86	6,563	300,966	198,842	Nov 14 12:10 PM
Mackin James P	President & CEO	Nov 13 '25	Sale	45.86	34,210	1,568,802	800,993	Nov 14 12:09 PM
Holloway Jean F	SVP, General Counsel	Nov 13 '25	Sale	45.86	5,761	264,188	163,408	Nov 14 12:08 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 13 '25	Sale	45.86	4,993	228,969	56,641	Nov 14 12:07 PM
Davis John E	Officer	Nov 14 '25	Proposed Sale	44.67	6,393	285,575		Nov 14 10:35 AM
Horton Amy	Officer	Nov 13 '25	Proposed Sale	45.86	3,482	159,679		Nov 13 04:39 PM
Holloway Jean F	Officer	Nov 13 '25	Proposed Sale	45.86	5,761	264,190		Nov 13 04:25 PM
Mackin James P	Officer	Nov 13 '25	Proposed Sale	45.86	34,210	1,568,812		Nov 13 04:19 PM
Stanton Marshall S.	Officer	Nov 13 '25	Proposed Sale	45.86	4,993	228,970		Nov 13 04:16 PM
Davis John E	Officer	Nov 13 '25	Proposed Sale	45.86	6,563	300,968		Nov 13 04:09 PM
Holloway Jean F	SVP, General Counsel	Nov 11 '25	Option Exercise	11.03	10,000	110,300	179,169	Nov 12 08:12 PM
Holloway Jean F	SVP, General Counsel	Nov 11 '25	Sale	46.18	10,000	461,800	169,169	Nov 12 08:12 PM
Holloway Jean F	SVP, General Counsel	Nov 10 '25	Sale	44.62	2,960	132,072	169,169	Nov 12 08:12 PM
Mackin James P	President & CEO	Nov 10 '25	Sale	44.62	17,580	784,402	835,203	Nov 12 08:08 PM
Davis John E	Chief Commercial Officer	Nov 10 '25	Sale	44.62	3,373	150,500	205,405	Nov 12 08:07 PM
Horton Amy	VP, Chief Accounting Officer	Nov 10 '25	Sale	44.62	1,789	79,823	144,862	Nov 12 08:06 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 10 '25	Sale	44.62	2,566	114,492	61,634	Nov 12 08:05 PM
Stanton Marshall S.	Officer	Nov 11 '25	Proposed Sale	44.62	2,566	114,492		Nov 12 09:25 AM
Mackin James P	Officer	Nov 10 '25	Proposed Sale	44.62	17,580	784,400		Nov 12 08:31 AM
Holloway Jean F	Officer	Nov 11 '25	Proposed Sale	46.18	10,000	461,800		Nov 12 08:30 AM
Holloway Jean F	Officer	Nov 11 '25	Proposed Sale	44.62	2,960	132,072		Nov 12 08:26 AM
Horton Amy	Officer	Nov 10 '25	Proposed Sale	44.62	1,789	79,823		Nov 12 08:20 AM
Davis John E	Officer	Nov 10 '25	Proposed Sale	44.62	3,373	150,500		Nov 12 08:15 AM
Stanton Marshall S.	SVP, Clinical & MD Affair	Aug 27 '25	Option Exercise	11.03	18,200	200,746	82,400	Aug 28 06:08 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Aug 27 '25	Sale	44.02	18,200	801,219	64,200	Aug 28 06:08 PM
MARSHALL STANTON	Officer	Aug 27 '25	Proposed Sale	44.02	18,200	801,211		Aug 27 05:39 PM
Holloway Jean F	SVP, General Counsel	Aug 25 '25	Option Exercise	11.03	10,000	110,300	182,129	Aug 26 10:39 AM
Holloway Jean F	SVP, General Counsel	Aug 25 '25	Sale	44.37	10,000	443,700	172,129	Aug 26 10:39 AM
JEAN F HOLLOWAY	Officer	Aug 25 '25	Proposed Sale	44.37	10,000	443,700		Aug 25 09:32 PM
Mackin James P	President & CEO	Aug 15 '25	Sale	42.32	12,500	528,988	852,783	Aug 19 11:28 AM
Mackin James P	Officer	Aug 15 '25	Proposed Sale	42.32	12,500	528,991		Aug 15 02:43 PM
Holloway Jean F	SVP, General Counsel	Aug 12 '25	Option Exercise	26.24	16,975	445,424	195,485	Aug 14 09:58 AM
Holloway Jean F	SVP, General Counsel	Aug 12 '25	Sale	43.01	23,356	1,004,610	172,129	Aug 14 09:58 AM
Davis John E	Chief Commercial Officer	Aug 12 '25	Option Exercise	26.24	10,802	283,444	219,580	Aug 14 09:56 AM
Davis John E	Chief Commercial Officer	Aug 12 '25	Sale	43.67	10,802	471,756	208,778	Aug 14 09:56 AM
JOHN E DAVIS	Officer	Aug 12 '25	Proposed Sale	43.67	10,802	471,753		Aug 12 05:58 PM
JEAN F HOLLOWAY	Officer	Aug 12 '25	Proposed Sale	43.01	23,356	1,004,606		Aug 12 05:19 PM
Horton Amy	VP, Chief Accounting Officer	Aug 08 '25	Option Exercise	29.62	7,992	236,723	154,643	Aug 11 04:37 PM
Horton Amy	VP, Chief Accounting Officer	Aug 08 '25	Sale	38.49	7,992	307,612	146,651	Aug 11 04:37 PM
AMY HORTON	Officer	Aug 08 '25	Proposed Sale	38.49	7,992	307,612		Aug 08 04:07 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Jun 17 '25	Sale	29.50	15,000	442,500	64,200	Jun 18 11:48 AM
MARSHALL STANTON	Officer	Jun 17 '25	Proposed Sale	29.50	15,000	442,500		Jun 17 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AORT

Artivion Inc

Upgrade your FINVIZ experience